Ballentine Partners LLC Buys 4,058 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ballentine Partners LLC lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 24.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 20,889 shares of the company’s stock after acquiring an additional 4,058 shares during the period. Ballentine Partners LLC’s holdings in Takeda Pharmaceutical were worth $270,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TAK. NBC Securities Inc. lifted its stake in Takeda Pharmaceutical by 1.8% during the first quarter. NBC Securities Inc. now owns 43,539 shares of the company’s stock worth $614,000 after purchasing an additional 765 shares during the last quarter. Blair William & Co. IL boosted its stake in Takeda Pharmaceutical by 6.5% in the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock worth $176,000 after buying an additional 777 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its position in Takeda Pharmaceutical by 4.6% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 18,197 shares of the company’s stock valued at $253,000 after acquiring an additional 798 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Takeda Pharmaceutical by 5.4% during the first quarter. SG Americas Securities LLC now owns 16,099 shares of the company’s stock worth $224,000 after acquiring an additional 824 shares in the last quarter. Finally, Catalytic Wealth RIA LLC lifted its holdings in shares of Takeda Pharmaceutical by 4.0% in the 2nd quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company’s stock worth $281,000 after acquiring an additional 841 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $14.81 on Thursday. The stock has a market capitalization of $47.12 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. The company has a fifty day moving average of $14.10 and a 200-day moving average of $13.75. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $16.39. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. Equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.